Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Centrus Energy Corp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Centrus Energy Corp trades at $141.98 (market cap $2.91B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 4.3× Centrus Energy Corp's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Centrus Energy Corp for 29 Days on average.
| HALO | LEU | |
|---|---|---|
Market Cap | $12.58B | $2.91B |
Volume | 2,179,278 | 903,777 |
Sector | Health | Energy |
52-Week High | $115.22 | $436.00 |
52-Week Low | $61.63 | $138.18 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $14.49B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Centrus Energy (LEU) trades at $141.28, down 3.98% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18, P/S 6.68) but benefits from strong nuclear energy tailwinds and multiple HALEU supply contracts. Recent news highlights Centrus as a key player in the domestic nuclear fuel supply chain, with analyst consensus pointing to significant upside potential from current levels.
The investment case balances high execution risk against substantial growth opportunities in nuclear fuel enrichment. While profitability metrics show pressure (net margin declining to 10.23%), the company's strategic positioning in HALEU production and federal support create compelling long-term potential. Key risks include operational execution, valuation sensitivity, and nuclear industry adoption timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
